janus kinase (JAK) inhibitor in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
0.67 [0.52 ; 0.87 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, RECOVERY, 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, STOP-COVID (Guimarães), 2021 7 43% 11,129 low serious deathsdetailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18]
Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34]
STOP-COVID (Guimarães), 2021 0.49 [0.15; 1.62]
0.67 [0.52 ; 0.87 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, RECOVERY, 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, STOP-COVID (Guimarães), 2021 7 43% 11,129 low serious deaths (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 0.65 [0.39; 1.09]
COV-BARRIER, 2021 0.57 [0.41; 0.79]
0.59 [0.45 ; 0.78 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021 2 0% 2,558 low not evaluable clinical deteriorationdetailed results COV-BARRIER, 2021 1.12 [0.58; 2.16]
STOP-COVID (Guimarães), 2021 0.54 [0.27; 1.07]
0.78 [0.38 ; 1.60 ] COV-BARRIER, 2021, STOP-COVID (Guimarães), 2021 2 56% 1,525 low not evaluable clinical improvementdetailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
COV-BARRIER, 2021 1.25 [1.04; 1.50]
COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.22 [1.07 ; 1.39 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 5 10% 2,684 low serious clinical improvement (14-day)detailed results ACTT-2 (Kalil), 2020 1.30 [1.03; 1.64]
COV-BARRIER, 2021 1.28 [1.05; 1.56]
COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09]
1.31 [1.13 ; 1.52 ] ACTT-2 (Kalil), 2020, COV-BARRIER, 2021, COV-BARRIER (critically ill), 2022 3 0% 2,659 low not evaluable clinical improvement (28-day)detailed results COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81]
Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25]
1.92 [0.96 ; 3.82 ] COV-BARRIER (critically ill), 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 3 0% 126 low not evaluable clinical improvement (time to event analysis only)detailed results ACTT-2 (Kalil), 2020 1.16 [1.01; 1.33]
1.16 [1.01 ; 1.33 ] ACTT-2 (Kalil), 2020 1 0% 1,033 NA not evaluable death or ventilationdetailed results ACTT-2 (Kalil), 2020 0.69 [0.50; 0.95]
RECOVERY, 2022 0.90 [0.81; 0.99]
STOP-COVID (Guimarães), 2021 0.63 [0.41; 0.97]
0.78 [0.62 ; 0.99 ] ACTT-2 (Kalil), 2020, RECOVERY, 2022, STOP-COVID (Guimarães), 2021 3 56% 9,227 moderate not evaluable mechanical ventilationdetailed results ACTT-2 (Kalil), 2020 0.64 [0.44; 0.93]
RECOVERY, 2022 0.87 [0.74; 1.02]
Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48]
Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07]
0.72 [0.49 ; 1.06 ] ACTT-2 (Kalil), 2020, RECOVERY, 2022, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 4 49% 8,963 moderate not evaluable recoverydetailed results COV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20]
1.57 [0.77 ; 3.20 ] COV-BARRIER (critically ill), 2022 1 0% 101 NA not evaluable related AE (TRAE)detailed results Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60]
Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93]
1.26 [0.14 ; 11.07 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 0% 25 moderate not evaluable superinfectiondetailed results ACTT-2 (Kalil), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] ACTT-2 (Kalil), 2020 1 0% 1,033 NA not evaluable adverse eventsdetailed results Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71]
Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01]
0.12 [0.01 ; 1.37 ] Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021 2 2% 25 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-26 12:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 1046,727,818,606,954,964,962,963,1045
- roots T: 290
